Vivasor Appoints JP3E Development Corp. (JP 3E Holdings, Inc. (JPTE) Majority Owned Subsidiary) as Exclusive Strategic Representative in the Republic of Korea
Rhea-AI Summary
Vivasor, a clinical-stage biopharmaceutical holding company, has signed an Exclusive Strategic Representation Agreement with JP3E Development Corp, a majority-owned subsidiary of JP 3E Holdings (OTC:JPTE), appointing JP3E as its exclusive strategic representative and business development agent in the Republic of Korea.
JP3E will leverage its Korean network to identify and facilitate opportunities in licensing, commercialization, manufacturing, research collaborations, investment, and M&A, while definitive agreements will be executed directly between Vivasor and third parties. The agreement runs for an initial three-year term on a success-based model with no retainers or fixed monthly fees; JP3E may earn mutually agreed success fees for completed transactions it originates or facilitates. The partnership supports Vivasor’s diversified clinical pipeline, which the company describes as addressing markets exceeding $100 billion, including ADCs, oncology agents, a SARS-CoV-2 Mpro inhibitor, and a non-opioid pain therapy.
Positive
- Exclusive 3-year mandate in Korea positions JP3E as Vivasor’s sole strategic representative for approved business development activities.
- Success-based fee structure avoids retainers, monthly consulting fees, and advance payments, limiting fixed-cost burden for Vivasor.
- Access to Korea’s pharma and biotech ecosystem via JP3E’s established network across partners, investors, institutions, and government.
- Vivasor pipeline addressable market >$100 billion according to the company’s July 2026 corporate presentation, providing a large opportunity set for Korean partnerships.
Negative
- JP3E compensation is entirely success-based, so potential revenue from this mandate depends on transactions being completed by Vivasor or its affiliates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strategic Partnership to Accelerate Korean Market Entry, Business Development, and Long-Term Value Creation Across Vivasor's
SAN DIEGO, California and SEOUL, Republic of Korea, July 22, 2026 (GLOBE NEWSWIRE) -- Vivasor, Inc. ("Vivasor"), a clinical-stage biopharmaceutical holding company advancing a diversified portfolio of innovative therapies, today announced the execution of an Exclusive Strategic Representation Agreement with JP3E Development Corp. (OTC: JPTE) ("JP3E"), establishing JP3E as Vivasor's exclusive strategic representative and business development agent in the Republic of Korea.
The strategic collaboration positions Vivasor to capitalize on South Korea's rapidly expanding pharmaceutical and biotechnology ecosystem by identifying, coordinating, and facilitating high-value opportunities across licensing, commercialization, manufacturing, investment, and strategic partnerships.
Strategic Partnership Overview
Under the agreement, JP3E will leverage its established Korean business network to support Vivasor's market development initiatives across multiple categories:
- Strategic pharmaceutical and biotechnology partnerships
- Licensing and commercialization agreements
- Manufacturing and supply-chain collaborations
- Research and clinical development partnerships
- Strategic investment opportunities
- Corporate development and M&A opportunities
- Government, academic, institutional, and investor relationships
JP3E will facilitate introductions with qualified counterparties approved by Vivasor, while all definitive agreements—including licensing, manufacturing, commercialization, investment, and strategic partnership transactions—will be negotiated and executed directly between Vivasor and third parties.
Vivasor's Diversified Clinical Pipeline
Vivasor operates through four wholly integrated subsidiaries advancing six product candidates with human clinical experience across high-value therapeutic categories:
ACEA Pharmaceuticals
Developing Olgotrelvir (Ovydso™), an oral SARS-CoV-2 Mpro inhibitor approved in China, with ongoing global development and commercialization opportunities.
OQORY
Advancing next-generation antibody-drug conjugates (ADCs):
- OQY-3258 (TROP2 ADC) — targeting solid tumors including triple-negative breast cancer (TNBC), HR+/HER2− breast cancer, and head and neck squamous cell carcinoma (HNSCC)
- OQY-6129 (CD-38 ADC) — targeting multiple myeloma, amyloidosis, small-cell lung cancer, and autoimmune indications
ACEA Oncology
Developing:
- Fujovee (abivertinib / AC-5656) — a dual EGFR/BTK inhibitor for oncology applications
- AC-0939 (STI-8591) — a next-generation FLT3 inhibitor targeting acute myeloid leukemia (AML)
Fire Therapeutics
Developing RTX (RTX-OAK-301), a non-opioid TRPV1 agonist for knee osteoarthritis pain and cancer pain.
According to Vivasor's July 2026 corporate presentation, the company's pipeline represents an aggregate addressable market exceeding
Vivasor's leadership team includes experienced biotechnology and pharmaceutical executives with backgrounds in drug discovery, clinical development, regulatory affairs, manufacturing, and commercialization, including prior experience at Stratagene, CombiMatrix, Sorrento Therapeutics, Agilent, ACEA Therapeutics, Novartis, Pfizer, Eli Lilly, the U.S. FDA, Merck, and Scripps Research.
About JP3E Development Corp.
JP3E Development Corp., a majority owned subsidiary of JP 3E Holdings, Inc. (USA), is a Korea-based strategic development company focused on facilitating cross-border business opportunities between the United States, Republic of Korea, and global markets.
Headquartered in Seoul, JP3E specializes in:
- Strategic partnerships and business development
- International investment facilitation
- Technology commercialization
- Corporate growth initiatives
- Cross-border market expansion
- Strategic alliance development
JP3E serves as a strategic bridge connecting global companies with Korea's advanced pharmaceutical, biotechnology, technology, investment, and industrial ecosystems.
The company is led by John K. Park, Chairman & CEO, JP 3E Holdings, Inc., and Jaedong Yoon, Chief Executive Officer, JP3E Development Corp.
Leadership Commentary
Henry Ji, Ph.D., Chairman and Chief Executive Officer of Vivasor, stated:
"South Korea has emerged as one of the world's leading biotechnology and pharmaceutical innovation hubs. Our strategic partnership with JP3E is designed to accelerate our ability to identify high-quality partnerships, expand commercialization opportunities, and create sustainable long-term value for Vivasor and its shareholders. JP3E's established network and deep understanding of the Korean market position us to capitalize on strategic opportunities that align with our portfolio and growth objectives."
John K. Park, Chairman and CEO of JP 3E Holdings, Inc., stated:
"We are honored to support Vivasor's expansion into Korea. JP3E's mission is to connect innovative global companies with Korea's leading pharmaceutical companies, biotechnology organizations, investors, research institutions, and strategic partners. Vivasor's diversified clinical pipeline and experienced leadership team make this an ideal partnership to create meaningful opportunities for growth and value creation."
Jaedong Yoon, CEO of JP3E Development Corp., stated:
"JP3E Development Corp. is committed to building strategic relationships that accelerate innovation, commercialization, and international collaboration between Korea and global markets. We look forward to supporting Vivasor's long-term success in one of the world's most dynamic biotechnology markets."
Transaction Structure
The Exclusive Strategic Representation Agreement establishes JP3E as Vivasor's exclusive strategic representative and agent in the Republic of Korea for approved business development activities.
The relationship is structured on a success-based model with no retainer fees, monthly consulting fees, advance payments, or guaranteed compensation.
JP3E may receive mutually agreed success fees for transactions successfully originated, introduced, negotiated, or facilitated by JP3E and completed by Vivasor or its designated affiliates.
The initial term of the agreement is three years, with renewal provisions and continued cooperation between the parties.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding potential partnerships, commercialization opportunities, strategic transactions, clinical development programs, and future growth initiatives.
These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Forward-looking statements include, but are not limited to, expectations regarding product development, regulatory progress, commercialization, market opportunities, and strategic collaborations.
Vivasor and JP3E undertake no obligation to update any forward-looking statements except as required by applicable law.
Media & Investor Contacts
Vivasor, Inc. Investor Relations https://vivasor.io/
JP3E Development Corp. Corporate Communications https://jp3e.com/
JP 3E Holdings, Inc.
1300 Kuser Road, First Floor, Trenton, NJ 08619 · +1 (609) 581-1721 · info@jp3e.com · jp3e.com
Website: https://jp3e.com/ · www.jp3eholdings.com
X: x.com/JP3EHoldingsInc · Facebook: facebook.com/JP3E Holdings Inc
E-Mail: info@jp3e.com · K2Global Platform: https://k2global.tech/en
Source Documents:
- Vivasor–JP3E Exclusive Strategic Representation Agreement
- Vivasor Corporate Presentation / Confidential Investment Memorandum July 2026
- JP3E Development Corp. Corporate Information System (CIS)
